Compounding Pharmacies to Compete with Pharma Manufacturers?

As the media pressures the pharmaceutical industry to offer the same high-quality drugs at lower prices, industry experts actively seek ways to meet this growing demand. And the answer isn’t always from where you might expect. With companies such as Mylan making headlines for its price hike of the EpiPen—from $100 in 2007 to more than $600 in 2016—many companies are turning to their internal operations and assessing where money can be saved and the ultimate cost of the drug cut (while not impacting overall revenue). However, the answer may not be within pharmaceutical companies alone.